550997-55-2

Usage

Molecular Structure

The compound consists of a naphthalene ring with a cyano group attached at the first position, as well as hydroxyl and fluoro-hydroxyl groups attached at the third and seventh positions, respectively.

Classification

It belongs to the class of naphthalenes, which are polycyclic aromatic hydrocarbons.

Potential Applications

The compound may have potential applications in various fields, including pharmaceuticals, agrochemicals, and material science, due to its unique structure and properties.

Safety Precautions

It is important to handle this chemical with caution and follow proper safety protocols when working with it.

Upstream product

• 550998-36-2 3-(3-fluoro-4-methoxyphenyl)-7-hydroxy-1-naphthonitrile 
• 628-13-7 pyridine hydrochloride 
• 1049684-42-5 C₃₃H₄₄FNO₈P₂ 
• 158365-53-8 7-methoxy-3,4-dihydronaphthalene-1-carbonitrile 
• 158365-54-9 1-cyano-7-methoxynaphthalene 
• 19307-13-2 7-hydroxy-1-cyanonaphthalene 
• 6836-19-7 7-Methoxy-1-tetralone 
• 550998-30-6 3-bromo-7-hydroxy-1-cyanonaphthalene 

Downstream Products

• 1049684-43-6 C₁₇H₁₂FNO₈P₂ 
• 1049684-44-7 C₁₇H₁₁FNO₅P 
• 1049684-45-8 C₁₇H₁₁FNO₅P 
• 1049684-42-5 C₃₃H₄₄FNO₈P₂ 
• 858946-67-5 7-(tert-butyl-dimethyl-silanyloxy)-3-[4-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-phenyl]-1-(2,2-dibromo-vinyl)-naphthalene 
• 858946-68-6 7-(tert-butyl-dimethyl-silanyloxy)-3-[4-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-phenyl]-1-ethynyl-naphthalene 
• 858946-66-4 7-[[tert-butyl(dimethyl)silyl]oxy]-3-(4-[[tert-butyl(dimethyl)silyl]oxy]-3-fluorophenyl)-1-naphthaldehyde 
• 858946-09-5 8-ethynyl-6-(3-fluoro-4-hydroxy-phenyl)-naphthalen-2-ol 
• 858946-05-1 6-(3-fluoro-4-hydroxy-phenyl)-8-vinyl-naphthalen-2-ol 
• 858946-65-3 7-[[tert-butyl(dimethyl)silyl]oxy]-3-(4-[[tert-butyl(dimethyl)silyl]oxy]-3-fluorophenyl)-1-naphthonitrile 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION

The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

MONO-AND-DI-PHOSPHATES OF 3-(3-FLUORO-4-HYDROXY-PHENYL)-7-HYDROXY-NAPHTHALENE-1-CARBONITRILE

Compounds of formula II wherein each R1 and R2 is independently selected from H and —P(O)(R3)(R4), provided that at least one of R1 and R2 is —P(O)(R3)(R4); each R3 and R4 is independently selected from the group consisting of H, —OH, C1-C6 alkyl and C1-C6 alkoxy; or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising a compound of formula II, and methods of administering such compounds and compositions.

Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile

A process for making a compound of formula I and intermediate compounds thereof, wherein R1 is CN, F or Cl; R2 is H or Br; and R3 and R4 are each independently H or F. The compounds of formula I are useful in th

ERβ ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity

The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERβ were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERβ, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

Substituted phenyl naphthalenes as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structure 1wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.